Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Crofelemer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AI Boosts Jaguar Health's Crofelemer for Rare Disease Therapy
    AI Boosts Jaguar Health's Crofelemer for Rare Disease Therapy

    13 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-13/artificial-intelligence-ai-platforms-could-enhance-jaguar-healths-development-and-anticipated-com

    PHARMIWEB
    13 Apr 2026
    Share Share
    Napo Pharmaceuticals Co-Sponsoring Gastroenterology Conference
    Napo Pharmaceuticals Co-Sponsoring Gastroenterology Conference

    02 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-02/jaguar-health-family-company-napo-pharmaceuticals-co-sponsoring-pediatric-gastroenterology-conferenc

    PHARMIWEB
    02 Apr 2026
    Share Share
    FDA Backs Crofelemer Trial Extension In MVID Diseases
    FDA Backs Crofelemer Trial Extension In MVID Diseases

    18 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-18/fda-feedback-supports-extension-phase-for-jaguar-healths-clinical-trial-of-crofelemer-for-treatment

    PHARMIWEB
    18 Mar 2026
    Share Share
    Jaguar Health Secures $3M Payment From Future Pak For Mytesi
    Jaguar Health Secures $3M Payment From Future Pak For Mytesi

    03 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-03/jaguar-health-secures-an-additional-3-million-payment-from-future-pak-for-mytesi-and-canalevia-ca1

    PHARMIWEB
    03 Mar 2026
    Share Share
    Jaguar Inks $38M U.S. Crofelemer License Deal With Future Pak
    Jaguar Inks $38M U.S. Crofelemer License Deal With Future Pak

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-12/jaguar-health-enters-into-us-license-agreement-with-future-pak-for-crofelemer-providing-up-to-38

    PHARMIWEB
    12 Jan 2026
    Share Share
    Jaguar Health's Crofelemer Study Shows Promising Results
    Jaguar Health's Crofelemer Study Shows Promising Results

    06 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-06/article-about-groundbreaking-results-from-study-of-jaguar-healths-crofelemer-for-treatment-of-intes

    PHARMIWEB
    06 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.